Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy

• Published in: Scientific reports Vol. 12; no. 1; pp. 17443 - 8
• Main Authors: Inagaki, Tomonori, Hashizume, Atsushi, Hijikata, Yasuhiro, Yamada, Shinichiro, Ito, Daisuke, Kishimoto, Yoshiyuki, Torii, Ryota, Sato, Hiroyuki, Hirakawa, Akihiro, Katsuno, Masahisa
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.10.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/617; 692/617/375/364; Age; Androgens; Atrophy; Bulbo-Spinal Atrophy, X-Linked - diagnosis; Bulbo-Spinal Atrophy, X-Linked - genetics; Clinical trials; Consent; Disease; Disease Progression; Hospitals; Humanities and Social Sciences; Humans; multidisciplinary; Muscle Strength; Muscular Atrophy, Spinal - diagnosis; Neuromuscular diseases; Patients; Pressure; Respiration; Science; Science (multidisciplinary); Spinal and bulbar muscular atrophy; Tongue; University graduates; Walking
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-22322-w

This study aimed to develop a functional measurement that combines quantitative motor evaluation index of various body regions in patients with spinal and bulbar muscular atrophy (SBMA). We assessed subjects with SBMA and healthy controls with quantitative muscle strength measurements and functional scales. We selected tongue pressure, grip power, % peak expiratory flow (%PEF), timed walking test, and % forced vital capacity (%FVC) as components. By combining these values with Z-score, we created a functional composite (SBMA functional composite: SBMAFC). We also calculated the standardized response mean to compare the sensitivity of SBMAFC with that of existing measurements. A total of 97 genetically confirmed patients with SBMA and 36 age- and sex-matched healthy controls were enrolled. In the longitudinal analysis, the standardized response mean of SBMAFC was larger than that of existing rating scales. Receiver operating characteristic (ROC) analysis demonstrated that the SBMAFC is capable of distinguishing between subjects with early-stage SBMA and healthy controls. SBMAFC is more sensitive to disease progression than existing functional rating scales and is a potential outcome measure in clinical trials of SBMA.